Mode
Text Size
Log in / Sign up

Multiple sclerosis prevalence in Iran is 33.7 per 100,000 with significant upward trendsNew Data Shows Rising Rates of Multiple Sclerosis in Iran

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the statistically significant upward trend in MS prevalence and incidence in the Iranian population.

This meta-analysis synthesizes data from 142 individual studies across 56 articles to evaluate the epidemiology of multiple sclerosis (MS) in Iran. The analysis focuses on prevalence, incidence, and temporal trends of the disease within the Iranian population.

Key findings indicate an overall MS prevalence of 33.7 per 100,000 population (95%CI: 30.9-39.0). Gender-specific data show a prevalence of 76.0 per 100,000 in women (95%CI: 67.5-85.5) and 23.8 per 100,000 in men (95%CI: 21.0-27.0). The reported incidence of MS is 4.2 per 100,000 (95%CI: 2.7-6.6), with 6.7 per 100,000 in women (95%CI: 5.9-7.5) and 2.2 per 100,000 in men (95%CI: 1.9-2.4).

Furthermore, the analysis identifies a statistically significant upward trend in both the prevalence and incidence of MS over time (P < 0.001). No specific limitations or safety data were reported in the source. These findings provide a quantitative baseline for the regional burden of MS, though the specific drivers of the observed upward trends are not detailed in this synthesis.

How this fits prior evidence

This meta-analysis provides regional epidemiological data that complements existing evidence regarding MS trends in the Middle East and North Africa. Specifically, it provides a quantified prevalence of 33.7 per 100,000 and a statistically significant upward trend (P < 0.001), which aligns with the reported ecological correlation between rising EBV seroprevalence and MS cases in MENA regions.

A large review of 142 individual studies analyzed the prevalence and incidence of multiple sclerosis (MS) in Iran. The study looked at how many people have the condition and how many new cases appear each year, specifically comparing data between men and women.

The findings show that the overall prevalence of MS in the region is 33.7 per 100,000 people. However, the data shows a notable difference between genders. The prevalence for women is 76.0 per 100,000, while the prevalence for men is 23.8 per 100,000. The annual incidence of the disease is 4.2 per 100,000 people.

Most importantly, the data shows a statistically significant upward trend in both the prevalence and incidence of the condition over time. Because this is a large review of existing studies, it provides a broad look at regional trends. These findings help health officials understand how the condition is spreading and changing in the population.

What this means for you:
Data shows a significant upward trend in both the prevalence and incidence of multiple sclerosis in Iran.

Common questions

How common is multiple sclerosis in this region?

The study found an overall prevalence of 33.7 per 100,000 people. Specifically, the prevalence is 76.0 per 100,000 for women and 23.8 per 100,000 for men. These numbers help show how many people currently live with the condition in the studied area.

Are new cases of multiple sclerosis increasing?

Yes, the data shows a statistically significant upward trend in the incidence of multiple sclerosis over time. The current annual incidence is reported at 4.2 per 100,000 people, with 6.7 per 100,000 for women and 2.2 per 100,000 for men.

Is there a difference in how it affects men and women?

The data shows different rates for each gender. The prevalence for women is 76.0 per 100,000, while the prevalence for men is 23.8 per 100,000. Similarly, the annual incidence is higher for women at 6.7 per 100,000 compared to 2.2 per 100,000 for men.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
BACKGROUND: This study aimed to provide an updated estimate of the prevalence and incidence of multiple sclerosis (MS) in Iran. METHOD: To ensure the methodological rigor of this review, the protocol was developed in accordance with the MOOSE guidelines, and results were reported based on PRISMA statement. Two independent reviewers systematically searched national and international databases using MeSH terms from inception to January 1, 2026, without time restrictions. Data were pooled using Comprehensive Meta-Analysis software version 2, applying a random-effects model. A p-value of <0.05 was considered statistically significant. RESULTS: A total of 56 articles comprising 142 individual studies were included in meta-analysis. The overall prevalence of MS in Iran, based on 139 studies, was estimated at 33.7 per 100,000 population (33.7/ 100,000) (95%CI: 30.9-39.0). The prevalence was 23.8/ 100,000 (95%CI: 21.0-27.0) in men and 76.0/ 100,000 (95%CI: 67.5-85.5) in women. Based on 80 studies, the incidence of MS in Iran was estimated at 4.2/ 100,000 (95%CI: 2.7-6.6), with an incidence of 2.2/ 100,000 (95%CI: 1.9-2.4) in men and 6.7/100,000 (95%CI: 5.9-7.5) in women. Meta-regression analysis revealed a statistically significant upward trend in both prevalence and incidence of MS in Iran over time (P < 0.001). CONCLUSIONS: The findings demonstrate that both the prevalence and incidence of MS in Iran are considerable and have significantly increased over time, emphasizing the need for further investigation into context-specific risk factors within the country.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.